AstraZeneca

AstraZeneca Pharma India and Sun Pharmaceutical Industries have formed an exclusive brand partnership to promote and distribute SZC for hyperkalaemia treatment under separate brands

The deal is expected to be announced at the White House on Friday, said the people, who spoke on condition of anonymity because the plans are not yet public

AstraZeneca Pharma on Tuesday said it has received approval from the national drug regulator to market a cancer treatment drug in the country. The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, market, and distribute Trastuzumab Deruxtecan for an additional indication in India, the drug firm said in a statement. With this approval, Trastuzumab Deruxtecan is now indicated for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumours, who have received prior systemic therapy and have no satisfactory alternative treatment options, it added. This marks the first and only antibody drug conjugate in India with a tumour-agnostic indication, representing a significant advancement in precision oncology, the company said. "This milestone reflects our unwavering commitment to patient-centricity, scientific excellence, and equitable access to breakthrough therapies. By bringing Trastuzumab Deruxtecan to ..

The combination helped patients with a specific type of advanced non-small cell lung cancer live for 47.5 months at the median, the longest survival benefit ever reported

On Monday, AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the US

The decline in the company's share price came as its shares traded ex-date following the announcement of a ₹32 per share dividend

Here is the complete list of stocks that will trade ex-dividend on July 18, along with details of their dividend announcements

AstraZeneca Pharma shares rose after the company received regulatory approval to expand the use of its cancer drug Imfinzi (Durvalumab) in India.

Any such move would be a major blow to the UK stock market , which has seen a string of delistings and missed out on some major initial public offerings in recent months

Global bio-pharmaceutical company AstraZeneca has established its state-of-the-art Global Hub in Bengaluru investing Rs 166 crore to focus on development of AI-powered healthcare solutions, a top official said on Thursday. This marks the second major investment by AstraZeneca in July 2024 after it announced expansion of its Global Innovation and Technology Centre in Chennai with an outlay of Rs 250 crore. The new facility in Bengaluru is designed to accommodate nearly 1,300 employees including 400 new jobs. It will support the company's capabilities in AI-powered innovation across Research and Development, global business services, Information Technology and digital health operations, among others. The Global Hub in Bengaluru is dedicated to Research and Development, Global Business Services, Information Technology while the Global Innovation and Technology Centre in Chennai serves as a strategic hub for IT, Global Business Services. Following the expansion of the facility, the ...

AstraZeneca Pharma India rallied nearly 12 per cent after its net profit for the fourth quarter of the previous financial year jumped 48 per cent

Q4 net profit rises 48% to Rs 58.25 crore; revenue up 25.3% on strong growth across therapeutic areas, with oncology revenue up over 31% and record full-year sales

AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml solution for injection (brand name: Fasenra) for an additional indication.

"If tariffs were implemented in the range we have seen recently in other industries on medicines imported from Europe to the U.S., we would remain within the guidance range we indicated for 2025,"

AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons. The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing. It has now surrendered the marketing authorisation of the indication of Olaparib (Lynparza) 100mg and 150mg, the filing added. "...since the date of receipt of marketing authorisation for the said indications i.e. November 17, 2023, till date, we have never marketed the said indication in India," the company said, adding, "the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons." The drug is indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate ..

Sodium zirconium cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients

Five of top 20 drug introductions target cancer, reflecting its rising incidence in India

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts surveyed by Bloomberg

The decision to ditch the development of an existing facility in the Speke area of Liverpool comes at a time when Prime Minister Keir Starmer is pushing hard to drum up investment in Britain

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from CDSCO